Combined blockade of VEGFR-3 and VLA-1 markedly promotes high-risk corneal transplant survival

Investigative Ophthalmology and Visual Science

Volumn 52, Issue 9, 2011, Pages 6529-6535

  Zhang, Hui ^a   Grimaldo, Sammy ^a   Yuen, Don ^a   Chen, Lu ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VASCULOTROPIN RECEPTOR 3; VERY LATE ACTIVATION ANTIGEN 1; NEUTRALIZING ANTIBODY;

ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORNEA NEOVASCULARIZATION; CORNEA TRANSPLANTATION; FLUORESCENCE MICROSCOPY; GRAFT REJECTION; GRAFT SURVIVAL; IMMUNOFLUORESCENCE TEST; KAPLAN MEIER METHOD; LYMPHANGIOGENESIS; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RECEPTOR BLOCKING; SLIT LAMP; TREATMENT OUTCOME; ANIMAL; BAGG ALBINO MOUSE; C57BL MOUSE; CORNEA; DRUG ANTAGONISM; DRUG EFFECT; INTRAPERITONEAL DRUG ADMINISTRATION; LYMPH VESSEL; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; RISK FACTOR; VASCULARIZATION;

ANIMALS; ANTIBODIES, NEUTRALIZING; CORNEA; CORNEAL NEOVASCULARIZATION; CORNEAL TRANSPLANTATION; GRAFT SURVIVAL; INJECTIONS, INTRAPERITONEAL; INTEGRIN ALPHA1BETA1; LYMPHANGIOGENESIS; LYMPHATIC VESSELS; MALE; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICROSCOPY, FLUORESCENCE; RISK FACTORS; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-3;

EID: 80054704709     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.11-7454     Document Type: Article

References (35)

1. Niederkorn JY. High-risk corneal allografts and why they lose their immune privilege. Curr Opin Allergy Clin Immunol. 2010;10: 493-497.
2. Chen L. Ocular lymphatics: state-of-the-art review. Lymphology. 2009;42:66-76.
3. Chong EM, Dana MR. Graft failure IV: immunologic mechanisms of corneal transplant rejection. Int Ophthalmol. 2008;28:209-222.
4. Lechler RI, Sykes M, Thomson AW, Turka LA. Organ transplantation-how much of the promise has been realized? Nat Med. 2005;11:605-613.
5. Cursiefen C, Chen L, Dana MR, Streilein JW. Corneal lymphangiogenesis: evidence, mechanisms, and implications for corneal transplant immunology. Cornea. 2003;22:273-281.
6. Streilein JW, Yamada J, Dana MR, Ksander BR. Anterior chamberassociated immune deviation, ocular immune privilege, and orthotopic corneal allografts. Transplant Proc. 1999;31:1472-1475.
7. Group TCCTSR. The collaborative corneal transplantation studies (CCTS): effectiveness of histocompatibility matching in high-risk corneal transplantation. Arch Ophthalmol. 1992;110:1392-1403.
8. Chen L, Hann B, Wu L. Experimental models to study lymphatic and blood vascular metastasis. J Surg Oncol. 2011;103:475-483.
9. Liu Y, Hamrah P, Zhang Q, Taylor AW, Dana MR. Draining lymph nodes of corneal transplant hosts exhibit evidence for donor major histocompatibility complex (MHC) class II-positive dendritic cells derived from MHC class II-negative grafts. J Exp Med. 2002;195: 259-268.
10. Tammela T, Alitalo K. Lymphangiogenesis: molecular mechanisms and future promise. Cell. 2010;140:460-476.
11. Dietrich T, Bock F, Yuen D, et al. Cutting edge: lymphatic vessels, not blood vessels, primarily mediate immune rejections after transplantation. J Immunol. 2010;184:535-539.
12. Cueni LN, Detmar M. The lymphatic system in health and disease. Lymphat Res Biol. 2008;6:109-122.
13. Kerjaschki D, Huttary N, Raab I, et al. Lymphatic endothelial progenitor cells contribute to de novo lymphangiogenesis in human renal transplants. Nat Med. 2006;12:230-234.
14. Geissler HJ, Dashkevich A, Fischer UM, et al. First year changes of myocardial lymphatic endothelial markers in heart transplant recipients. Eur J Cardiothorac Surg. 2006;29:767-771.
15. Brown P. Lymphatic system: unlocking the drains. Nature. 2005; 436:456-458.
16. Bock F, Onderka J, Dietrich T, Bachmann B, Pytowski B, Cursiefen C. Blockade of VEGFR3-signalling specifically inhibits lymphangiogenesis in inflammatory corneal neovascularisation. Graefes Arch Clin Exp Ophthalmol. 2008;246:115-119.
17. Chen L, Hamrah P, Cursiefen C, et al. Vascular endothelial growth factor receptor-3 mediates induction of corneal alloimmunity. Nat Med. 2004;10:813-815.
18. Kubo H, Cao R, Brakenhielm E, Makinen T, Cao Y, Alitalo K. Blockade of vascular endothelial growth factor receptor-3 signaling inhibits fibroblast growth factor-2-induced lymphangiogenesis in mouse cornea. Proc Natl Acad Sci U S A. 2002;99:8868-8873.
19. Grimaldo S, Yuen D, Ecoiffier T, Chen L. Very late antigen-1 mediates corneal lymphangiogenesis. Invest Ophthalmol Vis Sci. 2011;52:4808-4812.
20. Chen L, Huq S, Gardner H, de Fougerolles AR, Barabino S, Dana MR. Very late antigen 1 blockade markedly promotes survival of corneal allografts. Arch Ophthalmol. 2007;125:783-788.
21. Yuen D, Pytowski B, Chen L. Combined blockade of VEGFR-2 and VEGFR-3 inhibits inflammatory lymphangiogenesis in early and middle stages. Invest Ophthalmol Vis Sci. 2011;52:2593-2597.
22. Zhang H, Hu X, Tse J, Tilahun F, Qiu M, Chen L. Spontaneous lymphatic vessel formation and regression in the murine cornea. Invest Ophthalmol Vis Sci. 2011;52:334-338.
23. Yamagami S, Dana MR, Tsuru T. Draining lymph nodes play an essential role in alloimmunity generated in response to high-risk corneal transplantation. Cornea. 2002;21:405-409.
24. Ecoiffier T, Yuen D, Chen L. Differential distribution of blood and lymphatic vessels in the murine cornea. Invest Ophthalmol Vis Sci. 2010;51:2436-2440.
25. Dana MR, Streilein JW. Loss and restoration of immune privilege in eyes with corneal neovascularization. Invest Ophthalmol Vis Sci. 1996;37:2485-2494.
26. Yuen D, Leu R, Sadovnikova A, Chen L. Increased lymphangiogenesis and hemangiogenesis in infant cornea. Lymph Res Biol. 2011; 9:109-114.
27. Yamagami S, Dana MR. The critical role of lymph nodes in corneal alloimmunization and graft rejection. Invest Ophthalmol Vis Sci. 2001;42:1293-1298.
28. Dana MR, Yamada J, Streilein JW. Topical interleukin 1 receptor antagonist promotes corneal transplant survival. Transplantation. 1997;63:1501-1507.
29. Qian Y, Boisgerault F, Benichou G, Dana MR. Blockade of CD40-CD154 costimulatory pathway promotes survival of allogeneic corneal transplants. Invest Ophthalmol Vis Sci. 2001;42: 987-994.
30. Bachmann BO, Bock F, Wiegand SJ, et al. Promotion of graft survival by vascular endothelial growth factor a neutralization after high-risk corneal transplantation. Arch Ophthalmol. 2008; 126:71-77.
31. Sidiropoulos PI, Boumpas DT. Lessons learned from anti-CD40L treatment in systemic lupus erythematosus patients. Lupus. 2004; 13:391-397.
32. Hynes RO. Integrins: bidirectional, allosteric signaling machines. Cell. 2002;110:673-687.
33. Stepp MA. Corneal integrins and their functions. Exp Eye Res. 2006;83:3-15.
34. Zhang X, Groopman JE, Wang JF. Extracellular matrix regulates endothelial functions through interaction of VEGFR-3 and integrin alpha5beta1. J Cell Physiol. 2005;202:205-214.
35. Wang JF, Zhang XF, Groopman JE. Stimulation of beta 1 integrin induces tyrosine phosphorylation of vascular endothelial growth factor receptor-3 and modulates cell migration. J Biol Chem. 2001; 276:41950-41957.